Detalhe da pesquisa
1.
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV Clin Trials
; 13(3): 119-30, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22592092
2.
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Lancet
; 372(9639): 646-55, 2008 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-18722869
3.
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
AIDS
; 17(18): 2603-14, 2003 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-14685054
4.
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
J Int Assoc Physicians AIDS Care (Chic)
; 3(3): 92-8, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15573713
5.
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.
J Am Heart Assoc
; 7(4)2018 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29440007
6.
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
J Acquir Immune Defic Syndr
; 53(3): 323-32, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20032785